|Bid||80.76 x 1000|
|Ask||80.80 x 1100|
|Day's Range||79.84 - 81.39|
|52 Week Range||36.92 - 84.10|
|Beta (3Y Monthly)||1.82|
|PE Ratio (TTM)||70.34|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.50|
In 2013 Arthur Przybyl was appointed CEO of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). This report will, first, examine...
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
BAUDETTE, Minn., June 25, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Ranitidine Capsules, 150mg and 300mg. The current annual U.S. market for this product is approximately $40 million, according to Iqvia/IMS Health. Ranitidine Hydrochloride is an oral histamine H2-receptor antagonist with multiple indications. Ranitidine Capsules are indicated in: the short-term treatment of active duodenal, maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers, the treatment of pathological hypersecretory conditions, short-term treatment of active, benign gastric ulcer, maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers, treatment of GERD, treatment of endoscopically diagnosed erosive esophagitis, and maintenance of healing of erosive esophagitis.
BAUDETTE, Minn. , June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin ...
BAUDETTE, Minn., June 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that it has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3 million dollars in cash and up to $12.0 million in additional development and commercial milestones. As part of the agreement, ANI will pay a portion of gross profit generated from one of the injectable products to the commercial manufacturing partner. Included in the purchase price, ANI is also acquiring raw materials (API), manufacturing and packaging components, and reference drug valued at approximately $1.5M combined.
BAUDETTE, Minn., June 12, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) will present on June 18, 2019 at Raymond James' Life Sciences and MedTech Conference in New York City. Arthur Przybyl, President and CEO and Stephen Carey, Vice President and CFO, will present at 8:00 AM ET on Tuesday, June 18, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.
In this article we are going to estimate the intrinsic value of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by taking the...
ANI (ANIP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]
On a per-share basis, the Baudette, Minnesota-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, came to $1.30 per share. The drugmaker posted revenue of $52.9 ...
BAUDETTE, Minn. , May 9, 2019 /PRNewswire/ -- For the first quarter 2019: Net revenues of $52.9 million , an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share ...
BAUDETTE, Minn. , May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thursday, May 9, 2019 ...
ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For instance, the price of ANI Pharmaceuticals...
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.